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The hormone levels in women's bodies after menopause can require oestrogen replacement in order to reduce the severity of symptoms caused by its reduction. There is no doubt that HRT with bioidentical hormone therapy has the strength that no other therapy has nowadays, including isoflavones and other phytoestrogens [2] . The major problem is that it also has severe side effects. So, how can health professionals give accurate advice to menopausal women? The answer is not easy. The personal and family situation, assessment of cancer risk, and clinical examinations are steps actually taken by doctors with every female patient under their care. However, to whom goes the decision of undertaking HRT or other optional therapy? Considering that optional therapies with fewer side effects are becoming available, it might not be wise to disregard isoflavones as a potential therapy. According to pharmacokinetic data, these new plant derived molecules do not have the same efficiency as HRT, but today we also know that some isoflavones are better than placebos and that they show fewer side effects. Encouraged by the promising potential these compounds seem to have, the scientific community is seeking new molecules with the ability to mimic endogenous estrogens in order to find a therapy that presents less side effects and helps to reduce and/or prevent diseases related to menopause [3] .
Probably, the minor incidence of hormonaldependent tumours, or at least, its associated risk, made these soy-originating compounds so popular. Women all over the world are now turning their expectations towards over-the-counter (OTC) tablet preparations of isoflavones extracted from soy, mainly due to the regular news on this matter.
Quality control and standard criteria to establish confidence limits [low therapeutic dose -toxic levels] on isoflavone concentrations present in OTC tablet preparations of soy isoflavones must therefore be defined as soon as possible [4] [5] [6] . As long as there are still long-term trials objectively seeking a relationship between ingestion of soy and the relief of vasomotor menopausal symptoms with a decrease in hormonal related cancer, it is very important to control OTC tablet preparations of isoflavones extracted from soy and from other plants (e.g. black cohosh and red clover.
Nevertheless this therapeutic treatment using isoflavones is being heavily promoted, yet many research groups still have not found solid proof indicating that isoflavones can be used with safety or with benefits for osteoporosis, cardiovascular diseases, and preventing tumour processes [1, [7] [8] [9] . On the other hand, there are researchers who, based on many kinds of trials developed with menopausal women, affirm that isoflavones are a way to improve the health condition of these women both by the favourable effects on vasomotor symptoms and lipid profile.
One of the reasons researchers are not willing to support isoflavones as an innovative treatment is because of their receptor affinity characteristics. Isoflavones, such as genistein, are the most used in OTC tablet preparations of isoflavones and they have the major advantage that they form an easier linkage to the oestrogen beta-receptor. However, the good news ends here. In fact, genistein seems to be the only isoflavone that shows a significant rate of linkage to the beta-receptor rather than to the alphareceptor. Other isoflavones, like daidzein and glycitein, also commonly accompanying genistein, show the same rate of linkage to both the alpha-and beta-receptors [10] , with a consequent loss in therapeutic advantage. The fewer side effects that these substances have are due to the greater capacity to link to oestrogen beta-receptors. Accordingly, many questions continue without answers. Should it be investigated whether the linkage to both receptors will increase the risk of worse side effects associated with menopause? Even in very low concentration, compared with endogenous estrogens, will long-term use of pills containing isoflavones have the same side effects as HRT?
In the mean time, OTC tablet preparations of isoflavones extracted from soy are widely available and are promoted through claims of therapeutic bioeffects.
After the screening that we carried out with the crude extracts of soy from different cultivars [11] , and in order to evaluate the probable effect of OTC tablet preparations of isoflavones extracted from soy used for Post-Menopause complaints, we undertook a comparative analysis based on HPLC/DAD profiles of each brand of these formulas available in Portuguese Pharmacies.
For the determination of freshness, the antioxidant activity was measured, as we have proposed before with other crude materials [12] [13] .
HPLC/DAD profiles: OTC tablet preparations of isoflavones extracted from soy have been sold in Portuguese Pharmacies since 2001. First, only one was available (Formula-1/01), but now many others can be found. During the last 4 years we carried out in our laboratory a survey of these extracts and the results clearly lead to important conclusions.
The HPLC/DAD profiles of OTC tablet preparations of isoflavones extracted from soy were confirmed by LC/MS-MS and they show a different profile from that obtained previously with seeds. The results show that the main compounds in soy seeds are the 6-malonyl/6-acetyl derivatives of daidzin, glycitin and genistin [11] , whereas in the analysed OTC tablet preparations of isoflavones extracted from soy, the major components were the deacylated forms. The free aglycones, daidzein, glycitein and genistein, only appeared in very small amounts in seed extracts and in the OTC tablet preparations of isoflavones extracted from soy.
Other important data are that some brands seem to have the same extract in the same concentration (samples 7-9 from brand -4, compared to samples 10-12 from brand -5), yet the price for a daily dose is different (brand -4 with 0.69 € and brand -5 with 1.20 €).
The huge differences between the recommended daily doses are remarkable and need to be investigated. For example, as a therapeutic daily dose, brand-15 recommends 7.5 mg of isoflavones, brands-4, -5 and -13 100 mg, brand-3 120 mg and brand-8 160 mg. All this produces a therapeutic range with strange confidence limits and the basis of these results needs to be better evaluated. Maybe in brand-15, the low content of isoflavones will be under the therapeutic dose and for brands-3 and 8, the higher content may be up beyond the safe dose and may induce more side effects.
Another important finding is the stability of the isoflavones profile of the OTC preparations studied. During the years 2001-2005, the profile of the isoflavones included in the samples maintained in the laboratory at room temperature did not change, and this is important information relating to the degradation rate of these biocompounds. The extracts used to prepare these OTC tablet preparations are very stable in spite of the decrease observed in the antioxidant activity. The degradation certainly occurs with other compounds rather the isoflavones, daidzin, glycitin and genistin. These three glycosidic forms (that are hydrolysed in gut) are stable in tablets at least for 4 years (Campos et al. data not published). For the acetylgenistin, the increase of the mass relative to genistin corresponds to an acetyl unit, which was attached to the glucose unit since fragmentation of the [M+H] ion gave the same fragment previously detected for genistein.
LC/MS-MS identification of the isoflavones:

Antioxidant activity: Radical scavenging activity towards O 2
‫-·‬
(superoxide ion) was evaluated according to the method described by Kostyuk et al. [27] , which is based on the inhibition of the reduction of NBT by O 2 ‫-·‬ produced via photoreduction of riboflavin. Superoxide anion reacts with NBT to form formazan, which is detected at 560 nm. Addition of SOD to the assay mixture prevents the coloration, implying the involvement of superoxide in the reaction.
The concentrations that inhibited superoxide-driven reduction of NBT by 50% (IC 50 values) were determined. Values were calculated by averaging the results of three independent experiments performed in duplicate. To simplify the presentation only the data relating to the seeds with the minor and the major content in isoflavones is presented in Table 1 .
The results from the antioxidant activity assay reveal that this activity is dose dependent, but probably more related to the protein than isoflavone content. The standard isoflavones (genistein, genistin, biochanin A, daidzein and daidzin) gave very similar IC 50 values (> 66.7, μg/mL; the values did not show any structure -activity relationship). The standards used in this assay did not show activity; all of them had values higher than the control, except daidzein, which presented, for the same concentration, 66.7 μg/mL, an equivalent activity of 33%. Also, the amount tested was greater than usual for this assay and yet did not prove to be significant when compared with the results obtained with the seed extracts and with the extracts included in the OTC tablet preparations of isoflavones extracted from soy (See Table 1 ).
The extracts from seeds (crude material), with a very different content of isoflavones, also had a comparable IC 50 value for antioxidant activity (Table  1, In the samples of OTC tablet preparations of isoflavones extracted from soy, for example, the decrease for the first 2 years is enough to be used as a marker for freshness. For example: brand 5 had an antioxidant activity of 0.29+0.03 that decreased to 0.35+003 mg/mL during one year. A similar decrease was verified for the other brands. The most active OTC tablet preparation was brand-5 with a value of 0.29+0.03, a result close to the value obtained for fresh seeds of 0.27+0.02 mg/mL. It was not possible to establish a dose-dependent activity related to the isoflavone content but other components involved in these reactions will be degraded with time and induce a decrease of the antioxidant activity. This antioxidant parameter will be very helpful in a quality control proposal, because the freshness of the extracts can be verified using these results.
Current data are insufficient to draw definitive conclusions regarding the use of isoflavones as an alternative to oestrogen for hormone replacement in post-menopausal women. Although epidemiological and basic laboratory studies allude to the possible protective effects of soy isoflavones at specific target tissues, randomized, placebo-controlled clinical trials are necessary to address these important issues [1, 14] .
Despite all this, not much has been done to standardise the product while in a raw state and/or in the OTC tablet preparations of soy isoflavones. These extracts show different amounts of genistin and daidzin. For some seed sources, it is possible to find genistein derivatives as the main components and for others it is daidzein derivatives that are the prevalent bioactive components [6, 15] . After metabolism in the enterohepatic pathway, all the derivatives are hydrolysed and sulphono-or glucurono-genistein derivatives are produced from all the structures related to this isoflavone. For daizein what basically happens is the same, but an extra compound, equol, is produced in people who are "equol metabolizers". After hydrolysis, most of the isoflavones will be converted to genistein and daidzein, and accordingly we propose that the therapeutic dosage should be expressed in genistein equivalents for all compounds that are derived from genistein, and daidzein equivalents for all that are derived from this isoflavone.
Data in this form will make it easier to establish a therapeutic dose, dependent on the linkage to the alpha-and beta-oestrogen receptors (ERs) (theoretical calculations proposed by Campos and Matos [16] ).
The bioavailability of soy protein should be measured by its antioxidant activity and used as a parameter for quality control. Antioxidant activity can give important information regarding the freshness of soy extracts.
Pharmaceutical formulas with soy extracts available in the market have different isoflavone profiles, suggesting a potential to induce different therapeutic effects. If standardised extracts were used, the relationship between therapeutic effect/dosage would be more predictable. It is impossible to establish a relationship with the pharmacological assays without a standardization of the bioextracts [6, 17, 18] .
The ability that isoflavones have to mimic oestrogen molecules in their capacity to bind to ERs is evident in genistein and daidzein, as well as in their derivatives (genistin, biochanin A, daidzin, formononetin, glycitin and glycitein). The characteristic way isoflavones bind to ERs, mainly to β-receptors (only genistein does this) [10] , makes them promising molecules to replace hormones in therapeutics. Nevertheless, it should not be forgotten that they can also link to alpha-receptors in lower quantities, with a "remote" possibility of inducing hormonal-tumour proliferation [1, [19] [20] [21] .
Isoflavones used for HRT are found in a range of food and commercial preparations, such as purified isoflavone supplements, fortified foods, and mixed preparations containing these compounds. Two common sources of isoflavones are soy and red clover. Efficacy in clinical trials of soy foods and isoflavone supplements has been mixed; however, for women with frequent hot flushes, the North American Menopause Society (NAMS) advises physicians to consider suggesting their use. It was stated by the Society that in dosages of 40 to 80 mg per day, the potential for side effects seems minimal [22] . However, as we pointed out before, these doses should be determined in daidzein and genistin because the effect of these two compounds is different and the amount of both molecules that can be linked to the alpha-ERs needs to be calculated as a possible risk factor.
The aim of this work was to check the relationship between the OTC tablets preparations of isoflavones extracted from soy sold in the Portuguese Pharmacies. The results show that the levels of the isoflavone content can differ significantly. However the more important result is the understanding of the relationship between daidzein and genistein derivatives and that the very different bioactivity of these two molecules can induce a different therapeutic result. For example, 75 mg of genistein can induce a therapeutic effect resulting in 32.9 mg having an affinity for the beta-ERs and 0.645 mg for the alpha ERs. However, the same 75 mg, if daidzein, would only induce an affinity of 0.015 mg for the beta-ERs and 0.023 mg for the alpha ERs [16] . In the first case the bioactivity is much bigger than in the second one. Nevertheless, some authors have now pointed out the risk of low doses because they have been related to an increase in the promotion of the proliferation of tumours [23] .
Many papers have already been published in this field and most of them agree that the Food and Drug Administration recommendation for standardising herbal extracts for pharmaceutical purposes needs to be followed, but nothing has been done until now. We reiterate the need for the implementation of standardisation.
The method used to analyse the extracts and the final products needs to be simple, easy and relatively cheap. The protocol optimized by us for the HPLC/DAD profiles can be carried out in 2 hours with few reactions and the amounts used are small, resulting in low costs. The manual manipulations involve little time also. All of these parameters produce an inexpensive method that gives accurate results.
The evaluation of the antioxidant activity is very important in the quality control as an indicator of the freshness of the seeds and/or extracts and also because it is widely published that the antioxidant activity of these extracts is directly involved with prevention of cardiovascular problems. The decrease of LDL in serum is mainly due to the antioxidant bioactivity observed in soy extracts. As can be concluded from the assays for this parameter, the content of isoflavones is not relevant. Nevertheless its calculation is crucial.
Conclusions
The simplicity of the extracts for therapeutic purposes available as OTC tablet preparations of isoflavones extracted from soy in Portuguese Pharmacies, presumes that during the industrial preparation, the malonyl/acetyl derivatives are not extracted, and the respective glycosidic forms of the isoflavones daidzin, glycitin and genistin are the main structures obtained in the final mixture. Glycitin appears as a minor compound. This could be helpful to determine the bioeffect of these extracts since glycitin will be transformed during the enterohepatic cycle, first into daidzein and after that to equol, and this amount will be added to the equol produced by daidzin itself. For therapeutic purposes, and if the clinical trials arrive at a consensus, the "therapeutic window" could be determined from the amount of genistin (the more active compound) with the addition of the contribution from daidzin and glycitin. However, the different binding shown by these isoflavones to the alpha-and beta-ERs cannot be discharged in the calculation of either the therapeutic effect or in the safety dosage.
We will be continuing our screening by checking the extracts commercialized in other EU states.
The previous results [11] and the results presented in this paper show the possibility to breed or to buy soy seeds that consistently produce the same profile of isoflavones, assuming the industries want to produce a standardised extract for pharmaceutical purposes.
From the extracts analysed, it was clear that the malonyl and/or acetyl derivatives disappear from the final content and only daidzein, glycitein, genistein and the respective glucosides are present. It is thus not difficult for the suppliers to have standardised extracts. These biocompounds can also be prepared from the waste stream of soy processing where recovery of isoflavones yields mainly daidzin, glycitin and genistin [24] .
If they want to simplify the process (as the glucosidic forms are hydrolysed in the gut), only the aglycones need to be quantified. Glycitein will be transformed to daidzein after hydrolysis of the 6-methoxyl group. These metabolic processes involve low amounts of the compounds that will not be fully transformed into the respective bioactive molecules.
The antioxidant activity is very important in the quality control as the indicator of the freshness of the seeds and/or the extracts available for therapeutic proposals.
The full quality control proposed for soy extracts is seen as urgent. The standardisation of the extracts is not enough in itself to obtain a clear indication of the therapeutic bioactivity, but it can be crucial for this. Post-menopausal therapy using natural compounds, including isoflavones, was proposed a long time ago. Nevertheless, it is important to establish a consensus for various parameters [1] , such as standardization of the extracts, accurate quality control of the crude materials and the final products for inclusion in pharmaceuticals, toxicity levels, therapeutic dose (therapeutic window), side effects, and interactions. (Table 2) , with the specific claim for "relief of vasomotor menopausal symptoms"; 28 samples were derived from soy and 2 from black cohosh extracts.
Sample preparation for HPLC analysis: [25, 26] A representative amount of tablets was reduced to powder (250 mg) and homogenised. From this, an aliquot of 10 mg was weighed and added to 1000 μL of 50% aqueous ethanol in a 1.5 mL Eppendorf tube. The extraction was aided by use of vortexing and ultrasound for 45 min. The resultant mix was centrifuged (10000 rpm) and afterwards 10 μL of the supernatant was used for LC/MS-MS and HPLC/DAD analysis.
LC/MS-MS:
The previously referred to supernatant was filtered through a 0.45 μm PTFE filter, diluted with methanol (5 times) and analysed by LC/MS. All solvents used were HPLC grade. Liquid chromatography was carried out in an HP1050 system with UV detection operating at 260 nm, and equipped with a Supelco C18 (150 x 2.1 mm i.d.,5 μm) reversed-phase HPLC column and a Rheodyne injector with a 10 μL loop. The initial composition of the mobile phase was acetonitrile/water (10:90, v/v) containing 0.1% formic acid. In the initial 20 minutes of run time, the percentage of organic phase was increased to 17%. Isocratic conditions were maintained during 7 minutes and, again, the acetonitrile percentage was increased linearly to 45% in the following 18 minutes; this acetonitrile percentage was maintained constant for 15 minutes. The total run time was 60 minutes with a constant flow rate of 0. 8 mL/min. MS and MS/MS spectra were carried out in a Micromass (Manchester, UK) Quattro triple quadrupole mass spectrometer equipped with an electrospray source. Product ion spectra were obtained in positive ion electrospray mode. The cone voltage was set to 30V, and capillary voltage was maintained at 3.5 kV. The source and desolvation temperature were 80ºC and 150ºC, respectively. Tandem mass spectra were obtained using Ar as collision gas and the collision energy was optimized for each compound eluting from the HPLC system (15-35 eV). Spectra were recorded in centroid mode between m/z 50-500 in MS acquisition, and between m/z 50 and 5% above the mass of precursor ion, in MS/MS acquisition, with a scan duration of 0.2s and an interscan time of 0.1s. Spectra were processed using MassLynx TM 4 software.
Antioxidant activity assay: Superoxide radical scavenging activity was evaluated following the superoxide-driven reduction of nitro-blue tetrazolium (NBT) by photochemically reduced riboflavin [27] The final volume was 3 mL and the reaction mixtures contained phosphate buffer (16 mM, pH 7.8), EDTA (0.1 mM), TEMED (0.8 mM), NBT (85 µM) and riboflavin (6 µM). The assay was carried out at room temperature (22°C) under fluorescent lighting (20W, 20 cm). Reaction was stopped by switching off the light and plus the addition of 0.05 mL SOD (1mg/mL). Absorbance was measured at 560 nm.
HPLC/DAD method: Using a 0. 8 mL/min flow rate, H 2 0/CH 3 CN was pumped through a LichroSorb RP 18 column using gradient elution, and with a column temperature at 24ºC. Detection was performed online using the Diode Array Detector between λ 200 and λ 400nm . Flavonoid structures were compared to standards and the UV-spectra analysed according to principles developed by Campos and Markham [28] .
Apparatus: HPLC system (Gilson) and Diode Array Detector with Unipoint software; Jasco V-530 UV/VIS Spectrophotometer with "Spectra Manager" software. 
Standards and
